Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first‐line treatment for patients with EGFR mutant non‐small‐cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progresses. Osimertinib, a third‐generation EGFR‐TKI that...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Akamatsu, Hiroaki, Katakami, Nobuyuki, Okamoto, Isamu, Kato, Terufumi, Kim, Young Hak, Imamura, Fumio, Shinkai, Masaharu, Hodge, Rachel A., Uchida, Hirohiko, Hida, Toyoaki
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989837/
https://ncbi.nlm.nih.gov/pubmed/29697876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13623
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars